Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

  
 
  
Reply to this topic

RAC, Race Oncology Ltd
plastic
post Posted: May 4 2021, 04:56 AM
  Quote Post


Posts: 10,938
Thanks: 315


Stunning price trajectory. Now in a halt for a cap. raise. Probably at a big discount. This rise can't be sustainable.



--------------------
What did Uncle Mel do to us?
 
nipper
post Posted: Mar 9 2021, 01:29 PM
  Quote Post


Posts: 8,937
Thanks: 2740


In Reply To: nipper's post @ Mar 6 2021, 12:59 PM

Compelling Preclinical Breast Cancer Results
QUOTE
... Bisantrene killed breast cancer cells resistant to the current standard of care breast cancer drugs etoposide, palbocicclib, fulvestrant, tamoxifen, doxorubicin, epirubicin and cyclophosphamide
... Bisantrene was found to kill breast cancer cells from all common breast cancer subtypes including triple negative, ER+, and Her2+
... These results clearly support advancing Bisantrene into human breast cancer clinical trials




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
plastic
post Posted: Mar 6 2021, 06:31 PM
  Quote Post


Posts: 10,938
Thanks: 315


Another PRR or PBT by the look of it. No serious names in the registry, science looks light, scant detail on placements and just too much pump in it for me.

Wouldn't go near it with a barge pole.




--------------------
What did Uncle Mel do to us?
 
nipper
post Posted: Mar 6 2021, 12:59 PM
  Quote Post


Posts: 8,937
Thanks: 2740


Since listing in July 2016, RAC moved from around 30c a share to a high of 50c in early Jan 2018. Subsequent to that, the price declined and hit a low of 5.7c in July 2019.

With the repositioning of the board and management, and announcement of a new strategy for Bisantrene in Nov 2019, the price has taken off. There have been several placements of capital from prominent biotech investors along the way.



--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
plastic
post Posted: Mar 6 2021, 12:38 PM
  Quote Post


Posts: 10,938
Thanks: 315


Amazing price trajectory. Never gets a mention here. From under 5c to about four bucks in eighteen months.
Thats why the only reason to be on these boards is to find out what not to buy. Eg, ANP.




--------------------
What did Uncle Mel do to us?
 
nipper
post Posted: Feb 8 2021, 10:51 AM
  Quote Post


Posts: 8,937
Thanks: 2740


an interesting appointment to the Board

Ms Harney is the director of specialist consulting firm , Mary Harney Advisory , providing leadership, governance and strategic advice across innovation industries such as health, biotech and agriculture. She currently also serves as Chairman of private Australian biotech, CTxONE Pty Ltd, a cancer drug discovery and development company pursuing novel epigenetic and immuno-oncology programs.
She was formerly the CEO of Royal Australasian College of Surgeons; CEO of Gardiner Research Foundation; COO and Director of Office of Cancer Research for Peter MacCallum Hospital and COO of Cerylid Biosciences. Other former roles were with CSL, Amrad, BIOPROPERTIES and Royal Melbourne Hospital.

Race Chairman, Dr John Cullity commented:
QUOTE
Mary brings an exceptional pedigree to the Race Board and we welcome her appointment. She is a credentialed company director with strong commercial experience, based on multiple years developing assets in oncology and the broader healthcare landscape. Mary joins me as an independent director, so balancing Phil and Daniel's executive directorships


Ms Mary Harney commented,
QUOTE
I am joining the Board at a key moment in the development of both the company, and Bisantrene. Race holds unique and commercially powerful ingredients ... Bisantrene with a new development strategy which highlights multiple value points; new potential solutions to long-standing patient problems and a team of critical thinkers. I am humbled to be invited to bring my network and skillset to the table, from a long career in oncology, health and corporate governance.




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 


nipper
post Posted: Feb 5 2021, 10:14 AM
  Quote Post


Posts: 8,937
Thanks: 2740


Race has a strategy guided by a combination of impressive clinical data and Race's interest in further investigating the independent City of Hope pre-clinical observations that Bisantrene is a potent inhibitor of FTO (Fat mass and Obesity-associated protein). These unexpected findings encourage further preclinical and clinical evaluation across multiple cancer types under Pillar 1. Pillar 2 of the plan identified opportunity in Breast Cancer following positive preclinical data, while Pillar 3 extends the Acute Myeloid Leukemia (AML) program.

o Pillar 1 ... FTO inhibition focused on Melanoma and Clear Cell Renal Cell Carcinoma as proof of concept indications.
o Pillar 2 ... Breast cancer treatment as a safer chemotherapeutic agent with expanded therapeutic index
o Pillar 3 ... AML addressing legacy plans in adult and paediatric populations. Evaluation of extramedullary AML building on the Israel trial observation and clear unmet clinical need.


back at Dec highs of $2.20




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
nipper
post Posted: Dec 1 2020, 03:39 PM
  Quote Post


Posts: 8,937
Thanks: 2740


Race Oncology is an ASX listed precision oncology company with a Phase II/III cancer drug called Bisantrene.

QUOTE
Bisantrene is a potent inhibitor of the Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers. Race Oncology is exploring the use of Bisantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO overexpressing cancers.

The Company also has compelling clinical data for the use of Bisantrene as a chemotherapeutic agent with reduced cardiotoxicity in Acute Myeloid Leukaemia (AML), breast and ovarian cancers and is investigating its use in these areas.

https://www.raceoncology.com/

Developed in the 1970s, Bisantrene got to Phase III trials and did well, but the drug was not designed at clinical trial to show drug equivalence. Then the parent company American Cyanamid got into trouble and things lapsed.....
QUOTE
... it is not uncommon in the pharmaceutical industry, where up to 25% of all drugs that show promising Phase III results end up not being approved due to nonclinical reasons. It is a rare drug that does not suffer many near death experience during its development...

... what interests me about this is personal experience. A bout of ill health 4 years ago and I developed a fatty liver, and told I was pre diabetic. I did a Michael Mosley diet and rapidly dropped 10kg. And two melanomas appeared. Got them just in time; dodged a bullet, said the dermo.

QUOTE
Important scientific discoveries made over the last decade have identified dysregulation (loss of control) of RNA epigenetics as a key driver in cancer development. FTO was originally identified in the early 2000s from genome wide genetic association studies as linked to weight gain




--------------------
"Every long-term security is nothing more than a claim on some expected future stream of cash that will be delivered into the hands of investors over time. For a given stream of expected future cash payments, the higher the price investors pay today for that stream of cash, the lower the long-term return they will achieve on their investment over time." - Dr John Hussman

"If I had even the slightest grasp upon my own faculties, I would not make essays, I would make decisions." ― Michel de Montaigne
 
 



Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING